Chen Qi, Zhao Binbin, Tan Ziyang, Hedberg Gustav, Wang Jun, Gonzalez Laura, Mugabo Constantin Habimana, Johnsson Anette, Negrini Erika, Páez Laura Piñero, Rodriguez Lucie, James Anna, Chen Yang, Mikeš Jaromír, Bernhardsson Anna Karin, Reitzner Stefan Markus, von Walden Ferdinand, O'Neill Olivia, Barcenilla Hugo, Wang Chunlin, Davis Mark M, Carlson Lena-Maria, Pal Niklas, Blomgren Klas, Repsilber Dirk, Herold Nikolas, Lakshmikanth Tadepally, Kogner Per, Ljungblad Linda, Brodin Petter
Clinical Pediatrics Unit, Department of Women's and Children's Health, Karolinska Institutet, 17165 Stockholm, Sweden.
Childhood Cancer Research Unit, Department of Women's and Children's Health, Karolinska Institutet, 17177 Stockholm, Sweden.
Cell. 2025 Mar 6;188(5):1425-1440.e11. doi: 10.1016/j.cell.2024.12.014. Epub 2025 Jan 20.
Cancer is the leading cause of death from disease in children. Survival depends not only on surgery, cytostatic drugs, and radiation but also on systemic immune responses. Factors influencing these immune responses in children of different ages and tumor types are unknown. Novel immunotherapies can enhance anti-tumor immune responses, but few children have benefited, and markers of effective responses are lacking. Here, we present a systems-level analysis of immune responses in 191 children within a population-based cohort with diverse tumors and reveal that age and tumor type shape immune responses differently. Systemic inflammation and cytotoxic T cell responses correlate with tumor mutation rates and immune cell infiltration. Clonally expanded T cell responses are rarely detected in blood or tumors at diagnosis but are sometimes elicited during treatment. Expanded T cells are similarly regulated in children and adults with more immunogenic cancers. This research aims to facilitate the development of precision immunotherapies for children with cancer.
癌症是儿童疾病死亡的主要原因。存活率不仅取决于手术、细胞毒性药物和放疗,还取决于全身免疫反应。影响不同年龄和肿瘤类型儿童这些免疫反应的因素尚不清楚。新型免疫疗法可增强抗肿瘤免疫反应,但受益的儿童很少,且缺乏有效反应的标志物。在此,我们对一个基于人群队列中的191名患有不同肿瘤的儿童的免疫反应进行了系统水平分析,发现年龄和肿瘤类型对免疫反应的影响各不相同。全身炎症和细胞毒性T细胞反应与肿瘤突变率和免疫细胞浸润相关。在诊断时,血液或肿瘤中很少检测到克隆性扩增的T细胞反应,但在治疗期间有时会引发。在患有免疫原性更强癌症的儿童和成人中,扩增的T细胞受到类似的调控。本研究旨在促进针对癌症儿童的精准免疫疗法的开发。